No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Should Weakness in Shanghai Kaibao Pharmaceutical CO.,Ltd's (SZSE:300039) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Shanghai Kaibao Pharmaceutical (300039.SZ): Linggui Zhugan Decoction granules have completed pharmaceutical registration.
Shanghai Kaibao Pharmaceutical (300039.SZ) announced that the company recently received the approval from the National Medical Products Administration for Linggui Zhugan Decoction...
Individual Investors Invested in Shanghai Kaibao Pharmaceutical CO.,Ltd (SZSE:300039) up 13% Last Week, Insiders Too Were Rewarded
shanghai kaibao pharmaceutical (300039.SZ) and its subsidiaries have a total of 91 pharmaceuticals included in the National Medical Insurance Catalogue.
Shanghai Kaibao (300039.SZ) announced that the company and its wholly-owned subsidiary Shanghai Kaibao Xinyi (Xinxiang) Pharmaceutical Co. ...
Shanghai Kaibao PharmaceuticalLtd (SZSE:300039) Sheds 5.6% This Week, as Yearly Returns Fall More in Line With Earnings Growth
The Market Doesn't Like What It Sees From Shanghai Kaibao Pharmaceutical CO.,Ltd's (SZSE:300039) Earnings Yet